Aptar Pharma announced that it has launched a metered dose inhaler add-on sensor called HeroTracker Sense. According to Aptar, the device has been CE marked and is “pending FDA approval.” HeroTracker inhaler sensors were originally developed by Cohero Health, which was acquired by Aptar in 2020.
The company says that HeroTracker Sense, which snaps onto the MDI canister, monitors environmental, usage, and inhalation parameters and provides feedback to healthcare providers through the Aptar-Cohero Health BreatheSmart-Connect portal and to patients through the BreatheSmart mobile app.
Aptar Pharma President of Digital Health Sai Shankar said, “HeroTracker Sense is a strategic addition to Aptar’s portfolio of digital health solutions in the respiratory space, and underlines Aptar Pharma’s progress in the field of digital therapeutics, as well as our commitment to providing tools that will lead to an improvement in the lives of patients.”
Aptar Pharma Director of Business Development for Digital Healthcare Marcus Bates commented, “The launch of HeroTracker Sense positions Aptar’s digital respiratory portfolio as a world leading offering, providing insights into patient behaviors and how that will lead to a change in the way the patient interacts with their device, and their understanding of their indication. We see this as a product for the future and one that will demonstrate significant value, creating real world evidence that can aid the support of reimbursement models in numerous different markets.”
Read the Aptar Pharma press release.
